Trial Profile
A Phase II, Double-blind, Randomised, Parallel Group, Multi-centre Study Comparing gefitinib 250 mg (IRESSA?) with erlotinib 150 mg (Tarceva?) in Previously Treated Patients with Locally Advanced or Metastatic (Stage III or IV) Non-Small Cell Lung Cancer with High Epidermal Growth Factor Receptor Gene Copy Number (EGFR FISH +)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 03 Jun 2011
Price :
$35
*
At a glance
- Drugs Gefitinib (Primary) ; Erlotinib
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Acronyms ITEM
- Sponsors AstraZeneca AB
- 03 Jun 2011 New trial record